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Background: In Vietnam, the artemisinin-based combination therapy (ACT) of dihydroartemisinin-piperaquine is
currently used for first-line treatment of uncomplicated Plasmodium falciparum malaria. However, limited efficacy
and tolerability data are available on alternative forms of ACT in Vietnam in case there is a reduction in the
susceptibility of dihydroartemisinin-piperaquine. A study was conducted to compare the efficacy and tolerability of
two fixed-dose formulations of ACT, artemisinin–piperaquine (ArtequickW, ARPQ) and artesunate-amodiaquine
(Coarsucam™, ASAQ) for the treatment of P. falciparum malaria in south-central Vietnam.
Methods: A randomized, open-label trial was conducted comparing the efficacy of a two-day regimen of ARPQ
(~2.8 mg/kg artemisinin plus ~17.1 mg/kg of piperaquine per day) and a three-day regimen of ASAQ (~4.7 mg/kg
of artesunate plus ~12.6 mg/kg of amodiaquine per day) for the treatment of children and adults with
uncomplicated falciparum malaria. Primary efficacy endpoint was day 42, PCR-corrected, parasitological cure rate.
Secondary endpoints were parasite and fever clearance times and tolerability.
Results: Of 128 patients enrolled, 63 were administered ARPQ and 65 ASAQ. Of the patients who completed the
42 days follow-up period or had a recurrence of malaria, 55 were on ARPQ (30 children, 25 adults) and 59 were on
ASAQ (31 children, 28 adults). Recrudescent parasitaemia was PCR-confirmed for one patient in each treatment
group, with cure rates at day 42 of 98% (95% CI: 88–100) for both forms of ACT. The median parasite clearance
time was significantly slower in the ARPQ group compared with the ASAQ group (48 h vs. 36 h, P<0.001) and fever
clearance times were shorter in the ASAQ group (12 h vs. 24 h, P= 0.07). The two forms of ACT were well tolerated
with no serious adverse events.
Conclusion: Both forms of ACT were highly efficacious in the treatment of uncomplicated P. falciparum malaria.
Although the two-day course of ARPQ was equally as effective as the three-day course of ASAQ, parasite and fever
clearance times were shorter with ASAQ. Further studies are warranted in different regions of Vietnam to determine
the nationwide efficacy of ASAQ.
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In 2010, the World Health Organization (WHO) esti-
mated that half of the world’s population was at risk of
malaria, with an estimated 216 million cases and about
655,000 deaths [1]. For first-line treatment of uncompli-
cated Plasmodium falciparum malaria worldwide, WHO
recommends artemisinin-based combination therapy
(ACT), such as artemether-lumefantrine, artesunate-
amodiaquine, artesunate-mefloquine, artesunate-sulpha-
doxine-pyrimethamine and dihydroartemisinin-pipera-
quine [2]. Most of these formulations of ACT are
available as fixed-dosed co-formulations, facilitating
improved adherence, convenience and prevention
against misuse [3]. Of these, artemether-lumefantrine
(CoartemW, three-day six-dose regimen, total dose ~12/
72 mg/kg, respectively) and dihydroartemisinin-
piperaquine (ArtekinW, Duo-CotecxinW, Eurartesim™,
three-day three-dose regimen, total dose ~ 6/48 mg/kg,
respectively) have been shown to be highly efficacious
(day 42 cure rates >95%), safe and well tolerated in most
studies conducted so far in Southeast Asia [4-8].
Since the mid-1990s, artesunate plus mefloquine (two
and three-day regimens, total dose 12/25 mg/kg, re-
spectively), usually given as separate tablets, has been
the treatment of choice for multidrug-resistant falcip-
arum malaria in Southeast Asia, particularly along the
north-western border of Thailand, where mefloquine re-
sistance is prevalent [9]. Recent studies, however, along
the Thailand-Myanmar [10] and Cambodia-Thailand
[11] border regions have shown evidence of modest re-
sistance to artesunate plus mefloquine (three-day regi-
men), with a prolongation in parasite clearance times.
Reduced PCR-adjusted 42-day cure rates of about 80%
have also been reported in western and southern Cam-
bodia following treatment with artesunate plus meflo-
quine [12,13]. These findings of emerging ACT-resistant
P. falciparum malaria are of immense concern, as the
Cambodia-Thailand border region has been the epi-
centre of anti-malarial drug resistance [14], which histor-
ically has spread westward from South Asia to Africa
[5].
In Vietnam, the three-day fixed-dose combination regi-
men of dihydroartemisinin-piperaquine (ArterakineW) is
now the recommended first-line ACT for the treatment of
uncomplicated falciparum malaria [15]. Although
dihydroartemisinin-piperaquine has proved to be well
tolerated and highly efficacious against P. falciparum in
Vietnam [16,17], there is limited published data on the effi-
cacy and tolerability of other formulations of ACT in Viet-
nam. Because of the concern of reduced efficacy of
artesunate plus mefloquine in neighbouring Cambodia, it
is considered prudent to continue to evaluate alternative
forms of ACT in Vietnam in case there is a decline in the
efficacy of dihydroartemisinin-piperaquine. Recently, athree-day regimen of artesunate plus amodiaquine admi-
nistered as separate tablets was highly efficacious (PCR
adjusted 42-day cure rate of 98%) and well tolerated in the
treatment of uncomplicated falciparum malaria in Viet-
namese patients [17]. These encouraging findings with
artesunate plus amodiaquine prompted an assessment of
the efficacy and tolerability of a fixed-dose combination of
artesunate-amodiaquine (Coarsucam™) given over three
days at the same study site in Ninh Thuan Province,
south-central Vietnam where the previous artesunate plus
amodiaquine study was conducted. As a comparative treat-
ment arm, a two-day regimen of artemisinin–piperaquine
(ArtequickW) was also evaluated as the manufacturer
(Artepharm, Guangzhuo, People’s Republic of China)
advocates high efficacy, low cost, low toxicity, and ease of
administration with a short course of four tablets [18].
Methods
Study site, patients, and ethics
The study was conducted at Phuoc Chien Commune,
Thuan Bac District, Ninh Thuan Province in south-
central Vietnam, located about 300 km north of Ho Chi
Minh City. The commune has a population of about
4,000 people, with most belonging to the Ra-glai ethnic
group. Malaria transmission is low and occurs perenni-
ally with two peaks (May-June and October-November)
[19]. Anopheles dirus and Anopheles maculatus are the
main malaria vectors on the forested hill areas near the
commune [20]. Study participants were recruited among
patients presenting at the Phuoc Chien health station.
Patients with suspected clinical malaria were screened
and enrolled in the study if they met the following inclu-
sion criteria: age 5–60 years; a blood slide confirmed P.
falciparum mono-infection with a parasite density of
200–200,000 asexual parasites/μL; tympanic temperature
≥38°C at the time of enrolment or history of fever during
the preceding 24 h and willingness to be followed-up for
42 days after starting treatment. Exclusion criteria were
as follows: patients with symptoms and/or signs of
severe malaria; evidence of another serious medical
disease; a history of drug or alcohol abuse; anti-malarial
treatment within the preceding seven days; mixed
plasmodial infection or pregnant and lactating females.
Written informed consent was obtained from each adult
patient or from parents or legal guardians of enrolled
children. The study was ethically approved by the
Vietnam Ministry of Health, Vietnam People’s Army
Department of Military Medicine and the Australian
Defence Human Research Ethics Committee (Approval
No. 507/08).
Study design and treatment
In the open-label, randomized study the patients were
sequentially allocated to the two treatment groups:
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62.5 mg artemisinin and 375 mg piperaquine, Arte-
quickW, Artepharm Co., Ltd, Guangzhou, China) and
artesunate-amodiaquine (ASAQ, each tablet contained
100 mg artesunate and 270 mg amodiaquine, Coarsu-
cam™, Sanofi-Aventis, Morocco), with the first patient
receiving ARPQ, the second patient ASAQ, the third pa-
tient ARPQ, and so on. A weight-based regimen of
ARPQ (2.8 mg/kg artemisinin plus ~16.7 mg/kg pipera-
quine per day for two days) and ASAQ (~4.4 mg/kg
artesunate plus ~12.0 mg/kg amodiaquine per day for
three days) based on a 45 kg adult was rounded up or
down to the nearest half tablet. Both forms of ACT were
administered under direct observation and the drugs
were given with condensed milk. If a patient vomited the
drugs within 30 min, a full dose was readministered. The
rescue medication was a seven-day regimen of artesu-
nate (4 mg/kg on the first day and then 2 mg/kg daily
for six days) to be implemented if either parasitaemia
had not declined by at least 75% within 48 h of com-
mencing treatment with ARPQ or ASAQ or parasites
were still present on day 7 after starting treatment.
Patients with parasite reappearance were treated with
the seven-day regimen of artesunate for P. falciparum
and a three-day regimen of chloroquine (25 mg/kg) for
Plasmodium vivax as per national policy.
Although artesunate plus amodiaquine given as separ-
ate tablets has been reported to be highly efficacious
(cure rate 98%), the efficacy of the two-day regimen of
ARPQ, with a 42 day follow-up period is unknown.
WHO recommends that regardless of the treatment rate
of failure, a minimum sample size of 50 patients in clin-
ical trials is required in order for a study to be represen-
tative [21]. Thus, to achieve a minimum sample size of
50 patients for each treatment group, the aim was to re-
cruit 130 patients, with up to 15% of patients calculated
for loss during follow-up, withdraw, protocol violations
or mixed infections at admission identified subsequently
by PCR analysis [22]. The study was registered at Aus-
tralian New Zealand Clinical Trials Registry [23], with a
registration number of ACTRN12609000816257.
Laboratory investigations and follow-up
Clinical assessment and parasite density counts were
performed on days 0, 1, 2, 3, 7, 14, 21, 28, 35 and 42 or
on any day of recurrent malaria infection. Thick and
thin blood films were collected before and every 12 h
after commencement of treatment until blood films were
negative for three consecutive examinations. The
Giemsa-stained blood films were examined by two
microscopists and parasitaemia was quantified by exam-
ination of thick film fields (magnification × 1,000) against
200 leukocytes, assuming a total leukocytes count of
8,000/μL. Parasite clearance time was the time in hoursfrom starting treatment until the asexual parasite count
fell below detectable levels in thick blood films. Patient’s
tympanic body temperature was measured immediately
before and then every 12 h after starting treatment until
their temperature was <38°C for two consecutive days.
Fever clearance time was the time in hours from starting
treatment until the patient’s tympanic body temperature
remained <38°C for more than 48 h.
Blood spots on filter paper (3MM, Whatman) were
collected at the same time as blood smears. PCR parasite
genotyping was done to confirm plasmodial species
using the QIAamp DNA mini kit (Qiagen, Cat. #51304)
for DNA extraction, single round PCR detection and
identification of the four species, P. falciparum, P. vivax,
Plasmodium ovale and Plasmodium malariae using spe-
cific PCR primers [24]. In order to differentiate reinfec-
tion from recrudescence, multiplex PCR analysis was
performed on paired samples of P. falciparum DNA (day
0 and day of recurrence of parasitaemia) for allelic vari-
ation at three loci (merozoite surface proteins 1 and 2,
and glutamate rich protein). If at least one allele of the
recurrent parasitaemia was different to the before treat-
ment parasitaemia, the infection was considered a
reinfection.
Drug tolerability was assessed clinically. An adverse
event was defined as any sign or symptom that occurred
or became severe during the study regardless as to
whether it was related to the medication. Adverse events
were recorded by the physician at each drug administra-
tion and patients where asked to respond to the non-
leading question ‘How do you feel since you took the last
tablets?’ Since malaria infection, particularly during the
acute phase can cause adverse effects such as nausea, ab-
dominal pain, headache and dizziness, which often
makes it difficult to distinguish disease effects from drug
effects [25], no causal association was made between the
adverse events and the ACT.
Adult patients were invited to provide a blood sample
for drug analysis on day 7 after commencement of treat-
ment. Blood (5 mL) was obtained by venipuncture,
transferred to heparinized tubes and centrifuged at
1,400 g for 5 min. The separated plasma was transferred
to Nunc cryopreservation tubes and stored at −25°C.
The plasma samples were later transferred on dry-ice to
the Military Institute of Hygiene and Epidemiology in
Hanoi and then shipped to the Australian Army Malaria
Institute in Brisbane, where they were stored at −80°C
until analysis.
Drug analysis
The reference compounds of piperaquine, amodiaquine,
desethylamodiaquine and amodiaquine anologue were
donated by WWARN [26]. Plasma piperaquine concen-
trations were measured using solid phase extraction
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[27,28]. The interassay precision (i.e. coefficients of vari-
ation) for piperaquine was 10.3% at 10 ng/mL, 6.8% at
100 ng/mL and 6.7% at 500 ng/mL. The lower limit of
quantification (LLOQ) for piperaquine was 5 ng/mL
using 0.5 mL of plasma.
Plasma amodiaquine and its principal biologically ac-
tive metabolite, desethylamodiaquine concentrations
were measured by HPLC using a Agilent 1100 Series
consisting of Pump Model 1100-G1310A, Autosample
Model 1100-G131A and Absorbance UV/VIS Detector
Model G1314A set at 342 nm. The column used was a
Zorbax SB-CN cartridge (250 x 4.6 mm, 5 μm
USSF011231, Agilent) with Zorbax SB-CN (12.5 x
4.6 mm, 5 μm USSM003377) guard column. The mobile
phase consisted of acetonitrile: 1 M sodium perchlorate:
0.1 M phosphate buffer pH 2 (16:1:83, v/v/v) with a flow
rate of 1 mL/min. Samples were prepared for analysis as
follows: to a 10 mL polypropylene tube were added
plasma (500 μL), amodiaquine analogue (internal stand-
ard, 100 μL of 50 ng/mL) and 1 mL of acetonitrile. The
contents were vortexed for 30 sec followed by the
addition of 2 mL ammonia (specific gravity 0.88) and
5 mL methyl t-butyl ether. The contents were mixed for
20 min, centrifuged (1,600 g for 10 min) and the organic
phase transferred to a new polypropylene tube. The or-
ganic phase was evaporated at 40°C using instrument
grade air and the residue was reconstituted with 150 μL
of mobile phase of which 50 μL was injected onto the
HPLC. The retention times were about 6.5 min for
desethylamodiaquine, 8.5 min for amodiaquine and
11.0 min for the internal standard. The interday precision
was 9.6% at 5 ng/mL, 2.4% at 50 ng/mL and 0.4% at
500 ng/mL for amodiaquine. Corresponding interday pre-
cision for desethylamodiaquine were 4.0%, 6.2% and 6.0%.
The extraction efficiencies were 76% and 71% for amodia-
quine and desethylamodiaquine, respectively. The LLOQ
for amodiaquine and desethylamodiaquine was 5 ng/mL.
Statistical analysis
All data were analysed using SigmaStat (version 3.0 Jan-
del Scientific, CA, USA) and STATA 10.0 (StataCorp LP,
College Station, Texas, USA). Descriptive statistics were
used to summarize baseline values and demographic
data. Normally distributed and nonnormally distributed
data were compared using the Student’s t-test and the
Mann–Whitney U test, respectively. The primary effi-
cacy endpoint was PCR-adjusted 42-day cure rates after
starting treatment. Secondary endpoints were parasite
and fever clearance times and the occurrence of adverse
events. Demographic and efficacy data were assessed by
means of a per-protocol analysis, with recipients of res-
cue treatment counted as failures and new infections as
cured. A Kaplan-Meier survival analysis with a log-ranktest for statistical significance was applied. Differences in
proportions were compared using the χ2 or Fisher’s exact
test. Statistical significance was defined as a P<0.05.
Results
The study was conducted between May 2008 and
December 2009, with 128 patients enrolled consisting of
63 patients on ARPQ and 65 patients on ASAQ
(Figure 1). Overall, eight patients in the ARPQ group
and six patients in the ASAQ group did not fulfill the
per-protocol requirements. At enrolment, the two treat-
ment groups had similar demographic and clinical char-
acteristics (Table 1). Of the patients recruited, 54% (34/
63) on ARPQ and 52% (34/65) on ASAQ were children
(<15 years of age). The geometrical mean parasitaemia
was comparable between the two treatment groups
(17,912 parasites/μL for ARPQ and 16,776 parasites/μL
for ASAQ, P= 0.84). For both treatments, the geomet-
rical mean parasitaemia was about two-fold higher in
children compared with adults, but the differences were
not significant (ARPQ - P =0.13; ASAQ - P= 0.09). At
the time of admission, 64% (35/55) of patients on ARPQ
and 59% (35/59) on ASAQ were febrile.
Adults and children received comparable doses in
mg/kg body weight of ARPQ or ASAQ. For the two-
day regimen of ARPQ, adults were administered daily a
median (interquartile range, IRQ) of 2.8 mg/kg (2.5 to
3.1) artemisinin and 17.0 mg/kg (15.0 to 18.8) pipera-
quine. Corresponding values for children were 2.9 mg/
kg (2.2 to 3.2) artemisinin and 17.3 mg/kg (13.4 to
19.2) piperaquine. For the three-day regimen of ASAQ,
adults were administered daily 4.4 mg/kg (4.1 to 4.8)
artesunate and 11.8 mg/kg (11.0 to 13.0) amodiaquine.
Corresponding values for children were 5.0 mg/kg (4.2
to 5.3) artesunate and 13.5 mg/kg (11.3 to 14.4)
amodiaquine.
Treatment outcomes as per-protocol analysis for the
two treatment groups are summarized in Table 2. The
median parasite clearance time was significantly slower
in the ARPQ group compared with the ASAQ group
(48 h vs. 36 h, P<0.001) and parasite clearance tended
to be faster in adults than in children (ARPQ, 36 h vs.
48 h, P= 0.02 and ASAQ, 24 h vs. 36 h, P= 0.03). The
median fever clearance time was slower in the ARPQ
group than in the ASAQ group but the difference was
not significant (24 h vs. 12 h, P= 0.07).
For each treatment group only one patient had a recru-
descence by day 42 of follow-up. The patient in the ARPQ
group was a 14-year old male and at admission was febrile
with a parasitaemia of 7,096 parasites/μL. His parasite
clearance time was 48 h and his daily dose of artemisinin
and piperaquine were 3.3 mg/kg and 19.7 mg/kg, respect-
ively, which was slightly higher than the corresponding
median doses of 2.8 mg/kg and 17.1 mg/kg for the cured
Flow chart of study patients
59 (91%, 31 children, 28 adults) 
completed 42 days follow-up or 
had a recurrence of malaria
55 (87%; 30 children, 25 adults)
completed 42 days follow-up or 
had a recurrence of malaria
1 did not complete treatment
2 non-P. falciparum
monoinfection at admission to
study determined by PCR
3 protocol violation
2 lost to follow-up
65 assigned to ASAQ
34 children
31 adults




68 children (6-14 y)
60 adults (15-60 y)
2 did not complete treatment
1 non-P. falciparum
monoinfection at admission to
study determined by PCR
1 protocol violation
2 lost to follow-up
Figure 1 Trial profile. ARPQ: artemisinin-piperaquine; ASAQ: artesunate-amodiaquine.
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12 after starting treatment. In contrast to the ARPQ fail-
ure, the patient in the ASAQ group was a 28-year old
male and at admission was febrile with a parasitaemia of
23,092 parasites/μL. His parasite clearance time was 36 h
and his daily dose of artesunate and amodiaquine were
3.6 mg/kg and 9.8 mg/kg, respectively, which was less
than the corresponding median doses of 4.4 mg/kg and
11.9 mg/kg for the cured adults. He was diagnosed with a
recrudescence on day 33 after commencing treatment.
The PCR-adjusted cure rates were 98% for the ARPQ
group (95% CI: 88%-100%) and 98% (95% CI: 88%-100%)
for the ASAQ group (P= 0.96). Seven patients in the
ARPQ group and nine patients in the ASAQ group had
reinfections over the 42-day follow-up period. When
combining recrudescences and reinfections, the cure
rates were 87% (95% CI: 71%-91%) for ARPQ and 85%
(95% CI: 73%-92%) for ASAQ (P= 0.70). During the first
28 days of follow-up, no patient on ARPQ had a reinfec-
tion, whereas two patients on ASAQ were diagnosed with
new infections of P. falciparum on days 21 and 28. For
each treatment group, three patients with reinfectionswere diagnosed with P. vivax malaria. Although not used
in the analysis, of the protocol violations, one patient in
each treatment group had a parasitaemia greater than
200,000 parasites/μL and both were successfully treated.
Furthermore, the three patients with mixed infections of
P. falciparum and P. vixax malaria at admission (two on
ARPQ and one on ASAQ), based on subsequent PCR
analysis, none had a recurrence of malaria during the
follow-up period.
None of the patients had a serious adverse event and
both treatments were well tolerated. The most common
adverse events reported before and after treatment are
shown in Table 3 and they were generally mild in inten-
sity. The percentage of patients reporting adverse events
was comparable between the two treatment groups
before and after starting treatment. There was a marked
decline in adverse events 24 h after the first dose of each
ACT and by 48 h after commencing treatment most
patients were free of adverse events.
Seventy-two percent (18/25) of adults on ARPQ and
61% (17/28) of adults on ASAQ provided a blood sample
at day 7 after starting treatment. The median day 7
Table 2 Treatment outcomes as per-protocol after two-
day course of artemisinin-piperaquine [ARPQ, children
(n =30), adults (n = 25)] and a three-day course of
artesunate-amodiaquine [ASAQ, children (n= 31), adults
(n = 28)] in Vietnamese patients with Plasmodium
falciparum malaria
ARPQ ASAQ P value
Parasite clearance time, median h (IQR)
All patients 48 (12–72) 36 (24–72) <0.001
Children 48 (24–72) 36 (24–72) <0.001
Adults 36 (12–60) 24 (24–48) <0.001
Fever clearance time, median h (IQR)
All patients 24 (12–48) 12 (12–48) 0.07
Children 24 (12–48) 12 (12–48) 0.06
Adults 12 (12–24) 12 (12–48) 0.91
Recrudescence within
42 days, n/N (%)
1/55 (1.8%) 1/59 (1.7%) 0.51
Reinfection within
28 days, n/N (%)
0/55 (0%) 2/59 (3.4%) 0.51
Reinfection within
42 days, n/N (%)
7/55 (12.7%)a, b 9/59 (15.3%)b 0.91
a Mixed infection (Plasmodium falciparum and Plasmodium vivax) was
identified in 1 of 7 ARPQ recipients.
bPlasmodium vivax was identified in 3 of 7 recipients for both treatment
groups.
IQR - Interquartile range.
Table 1 Baseline characteristics of the patients according
to treatment as per-protocol
ARPQ ASAQ
No. of patients
All patients 55 59
Children 30 31
Adults 25 28
No. of males (%)
All patients 38 (69%) 42 (71%)
Children 21 (70%) 24 (77%)
Adults 17 (68%) 18 (64%)
Mean age (y) (±SD)
All patients 18.1 (12.9) 18.9 (12.7)
Children 9.1 (3.2) 10.2 (2.9)
Adults 29.0 (11.8) 28.5 (12.5)
Mean weight (kg) (±SD)
All patients 31.1 (13.0) 34.0 (12.3)
Children 21.8 (7.6) 24.4 (7.6)
Adults 43.6 (6.7) 44.6 (6.2)
Mean temperature (°C) (±SD)
All patients 38.6 (1.0) 38.3 (1.1)
Children 38.6 (0.9) 38.2 (1.2)
Adults 38.5 (1.3) 38.4 (1.0)
No. (%) of patients with temp ≥38°C
All patients 35 (64%) 35 (59%)
Children 21 (70%) 18 (58%)
Adults 14 (56%) 17 (61%)
Geometrical mean asexual Plasmodium falciparum/μL (range)
All patients 17,912 (617–162,527) 16,776 (590–114,550)
Children 23,785 (617–135,173) 23,522 (1,709-142,345)
Adults 12,746 (912–162,527) 11,450 (590–114,550)
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diaquine were 42 ng/mL (IQR, 23–63 ng/mL) and
54 ng/mL (IQR, 21–90 ng/mL), respectively. No amodia-
quine was present at day 7.
Discussion
The present study is the first to report on the efficacy
and tolerability of ASAQ (Coarsucam™) in Vietnam.
ASAQ was found to be highly efficacious (PCR-adjusted
42-day cure rate of 98%) in the treatment of uncompli-
cated P. falciparum malaria. The efficacy findings are in
accord with an earlier study, at the same study site in
south-central Vietnam, in which artesunate and amodia-
quine were coadministered as separate tablets to patients
[17]. When comparing the two studies, the admission
geometric mean parasitaemia was similar (all patients:
14,074 parasites/μL vs. 16,776 parasites/μL). The medianparasite clearance times, however, were significantly
longer in patients given ASAQ compared with patients
administered separate tablets (all patients 36 h vs. 24 h,
P= 0.007) despite the ASAQ group receiving a slightly
higher daily dose of the individual drugs (~4.7 mg/kg
artesunate plus ~12.6 mg/kg amodiaquine vs. ~4.4. mg/
kg artesunate plus ~10.6 mg/kg amodiaquine). Artesu-
nate and amodiaquine given either as a fixed-dose com-
bination or separate tablets was well tolerated in the
Vietnamese patients and is in accord with the two drugs
administered as different formulations (i.e. fixed vs. separ-
ate) for the treatment of P. falciparum in African children
[29]. The comparable efficacy and tolerability findings of
artesunate and amodiaquine given either as a fixed-dose
combination or separately was not unexpected as the
pharmacokinetics of the parent drugs and their principal
biologically active metabolites have been shown to be
similar in children with acute malaria [30].
Unlike the more commonly used fixed-dose combina-
tions of ACT such as artemether-lumefantrine and
dihydroartemisinin-piperaquine, there is limited data on
the efficacy of ARPQ. The fixed-dose combination was
developed by the Chinese as an alternative to
dihydroartemisinin-piperaquine (ArtekinW or Duo-
CotecxinW), with the manufacturer proposing the poten-
tial benefits of ARPQ’s cheaper cost of production and
improve compliance (i.e. two-day vs. three-day regimen).
Table 3 Adverse events in patients who completed the two-day course of artemisinin-piperaquine (ARPQ, n =62) and
the three-day course of artesunate-amodiaquine (ASAQ, n =63) in Vietnamese patients with Plasmodium falciparum
malaria
ARPQ Before treatment 24 h after 1st dose 24 h after 2nd dose 48 h after 2nd dose
Fever 88.7% (55/62) 29.0% (18/62) 1.6% (1/62) NR
Headache 87.1% (54/62) 48.4% (30/62) 1.6% (1/62) 1.6% (1/62)
Nausea 29.0% (18/62) 3.2% (2/62) NR NR
Stomach pain 1.6% (1/62) NR NR NR
Vomiting 1.6% (1/62) NR NR NR
Dizziness 27.4% (17/62) 3.2% (2/62) NR NR
Tiredness 61.3% (38/62) 25.8% (16/62) 3.2% (2/62) 1.6% (1/62)
Anorexia 43.5% (27/62) 9.7% (6/62) 1.6% (1/62) 1.6% (1/62)
ASAQ Before treatment 24 h after1st dose 24 h after 2nd dose 24 h after 3rd dose
Fever 82.5% (52/63) 20.6% (13/63) 3.2% (2/63) NR
Headache 95.2% (60/63) 46.0% (29/63) 3.2% (2/63) NR
Nausea 41.3% (26/63) 19.0% (12/63) 1.6% (1/63) NR
Stomach pain NR NR NR NR
Vomiting 3.2% (2/63) 3.2% (2/63) NR NR
Dizziness 25.4% (16/63) 3.2% (2/63) NR NR
Tiredness 69.8% (44/63) 30.2% (19/63) 3.2% (2/63) NR
Anorexia 46.0% (29/63) 20.6% (13/63) NR NR
NR – none reported.
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two-day regimens of ARPQ (one dose daily per day) and
dihydroartemisinin-piperaquine (ArtekinW twice daily
over two days) was carried out at Phuoc Chien Com-
mune in 103 patients, with a 28-day cure rate of 100%
for both forms of ACT [31]. However, the limitation of
the study was that the follow-up period was far too short
as a minimum of 42 days is required for forms of ACT
[2,32] that have lengthy terminal elimination half-lives,
such as piperaquine and mefloquine. Piperaquine has an
elimination half-life of about 23–33 days [33-35] and for
those patients who have failed dihydroartemisinin-
piperaquine treatment, recrudescences tend to occur
28 days after starting treatment [6,36].
Similar to the study carried out in 2004, the shorter
two-day regimen of ARPQ was highly efficacious, with a
PCR-adjusted cure rate of 98%. This compares favourably
with an earlier study at the same study site using three-
day regimens of dihydroartemisinin-piperaquine (Artera-
kineW) and artesunate plus amodiaquine given as separ-
ate tablets [17]. As with other studies using piperaquine
with dihydroartemisinin [6,17], ARPQ exhibited a better
post-treatment prophylactic effect due to the longer
elimination half-life of piperaquine (23–33 days) com-
pared with the shorter half-life of desethylamodiaquine
(9 days) [37] that is associated with ASAQ use. Although
ARPQ’s extended post-treatment prophylactic effect is
desirable the potential exists that low residual bloodpiperaquine concentrations may enhance the selection
and development of piperaquine resistant parasites. Note-
worthy, the three-day regimen of ASAQ cleared the P.
falciparum infections in the recipients faster than in
patients given the two-day regimen of ARPQ. In Thailand,
Krudsood et al. [38] showed that in a dose-ranging study
the two-day course of ARPQ was less effective than a
three-day regimen of ARPQ (PCR-adjusted cure rates,
75% vs. 98%) in treating Thai patients with uncomplicated
P. falciparum malaria, with a follow-up period of 28 days.
Presently, no marker exists that defines a consistent
method for identifying reduced susceptibility of para-
sites to forms of ACT, particularly to the artemisinin
component. Currently, prolongation of the parasite
clearance time has been used as an important early
warning sign of reduced artemisinin susceptibility. Most
patients cleared their infections within 48 h of com-
mencing their treatment with either ARPQ or ASAQ.
Of the patients, 16.7% (9/54) on ARPQ and 3.4% (2/58)
on ASAQ took up to 60 h to clear their infections.
However, up to 72 h was required to clear parasites in
one patient in each treatment group. Both patients
were children of 12 years of age, with an admission
parasitaemia of about 55,000 parasites/μL of blood.
They were not administered a sub-optimal dose of the
ACT, as they received a dose of each component above
the median mg/kg body weight for the treatment
group.
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such shorter dose regimens are not recommended by
WHO [2]. The rapid acting artemisinins have a parasite
reduction ratio (i.e. the fraction of infecting parasites
cleared per asexual blood cycle) of >104 and by them-
selves they need to be present at parasitological blood
concentrations during at least three asexual blood stages
to eliminate all parasites [39]. A limitation of the two-
day regimen of ARPQ is that the artemisinin component
is present for only one asexual cycle, as artemisinin has
a short elimination half-life of about 2.3 h [40], which
limits its exposure time to markedly reduce the parasitic
load. Thus, ARPQ relies heavily on piperaquine to
complete the clearance of all remaining parasites not
inhibited by its partner drug. In regions where parasites
are less susceptible to piperaquine, the two-day ARPQ
regimen is likely to be less effective as the blood pipera-
quine concentration would be insufficient to eliminate
all of the remaining parasites with the slower acting and
less active piperaquine.
Plasma concentrations of piperaquine and desethy-
lamodiaquine on day 7 have been found to correlate
with drug exposure (i.e. area under the plasma drug
concentration curve) and have been identified as
major determinants of therapeutic response to
dihydroartemisinin-piperaquine [41] and ASAQ [42].
The piperaquine day 7 concentration (median 42 ng/
mL) in adults on the two-day course of ARPQ (total
piperaquine base dose: 34 mg/kg) was not too dis-
similar to Papuan adult patients (mean 50 ng/mL)
treated with a three-day course of dihydroartemisinin-
piperaquine (total piperaquine base dose: 30 mg/kg)
[41]. The median plasma desethylamodiaquine con-
centration (54 ng/mL) in the Vietnamese patients is in
accord with metabolite levels measured in African chil-
dren (42 ng/mL - [42]) and adults (mean 62 ng/mL-
[43]) at day 7 after initiation of treatment.Conclusions
ARPQ and ASAQ were highly and equally efficacious in
the treatment of uncomplicated P. falciparum malaria in
children and adults in south-central Vietnam. However,
when comparing the two treatment regimens the three-
day course of ASAQ resulted in a faster parasite and
shorter fever clearance times than the two-day course of
ARPQ. These findings warrant further investigation of
the efficacy of ASAQ in other regions of Vietnam to
ascertain the potential value of the ACT as an alternative
option to dihydroartemisinin-piperaquine in case the
first-line ACT starts to fail in Vietnam.Competing interests
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